Discover Astex
Our Mission & Values
Our Leadership Team
Research Fellows
Our History
Corporate Social Responsibility
Environmental Sustainability
R&D
Clinical Pipeline
Pyramid™ Discovery Platform
Oncology and CNS Discovery
Sustaining Innovation Postdocs
Partnering
Our People & Culture
Career Opportunities
Media
Press Releases
Conferences & Meetings
Presentations & Publications
Interactive Scientific Resources
Interactive Software
Astex in the News
Contact
Click to open the search input field
Click to open the search input field
Search
Menu
Menu
You are here:
Home
1
/
Discover Astex
2
/
Our Leadership Team
3
/
UK – Discovery Research
4
/
Learn more about the discovery and approval of Kisqali
®
Link to: Astex and Otsuka announce results of the Phase 3 ASCERTAIN study of oral cedazuridine and decitabine fixed-dose combination (ASTX727) in subjects with MDS and CMML
Link to: Astex and Otsuka announce results of the Phase 3 ASCERTAIN study of oral cedazuridine and decitabine fixed-dose combination (ASTX727) in subjects with MDS and CMML
Astex and Otsuka announce results of the Phase 3 ASCERTAIN study of oral cedazuridine...
Link to: Proven fragment-based drug discovery platform – Pyramid™
Link to: Proven fragment-based drug discovery platform – Pyramid™
Proven fragment-based drug discovery platform – Pyramid™
Scroll to top
Scroll to top
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
Proven fragment-based drug discovery platform – Pyramid™